Biogen Plans Regulatory Filing for Aducanumab in Alzheimer ’s Disease Based on New Analysis of Larger Dataset from Phase 3 Studies

CAMBRIDGE, Mass. and TOKYO, Oct. 22, 2019 (GLOBE NEWSWIRE) -- Biogen (Nasdaq: BIIB) and Eisai, Co., Ltd. (Tokyo, Japan) today announced that, after consulting with the U.S. Food and Drug Administration (FDA), Biogen plans to pursue regulatory...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials